Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing ...

Metoclopramide use during early pregnancy was not associated with excess risk for congenital malformations. In the U.S., treatment of nausea and vomiting during early pregnancy usually involves ...

Metoclopramide (as HCl) 5mg; mint flavor. Allow tablet to dissolve on tongue. 10–15mg 4 times daily 30mins before meals and at bedtime. Intermittent symptoms: up to 20mg prior to provoking ...

Metoclopramide is used for the symptomatic treatment of post-operative or chemotherapy-induced nausea and vomiting, gastroesophageal reflux disease and gastroparesis. Metoclopramide is generally ...

Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. The exact mechanism of action of metoclopramide in the ...

Evoke Pharma (EVOK) shares rocketed 90% on positive data for its nasal drug Gimoti in the treatment of stomach paralysis in ...

Evoke Pharma Inc (NASDAQ:EVOK) shares are trading higher Monday after the company presented GLP-1 data for users with ...

Metoclopramide is a central dopamine D2-receptor antagonist used as an antiemetic and gastroprokinetic agent in dogs and cats 1,2,3,4. It has been used experimentally in pigeons as an antiemetic ...

Approved to treat diabetic gastroparesis, Gimoti is co-marketed with Eversana. Evoke underlined that nasal delivery provides ...

GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-yearStrong cumulative ...

FDA-approved drugs such as tradipant, metopimazine, and metoclopramide are gaining traction, whilst new treatments are in ...

Evoke Pharma reports positive results for a study on GIMOTI. Evoke Pharma stock has now tripled since early September.